The role of recombinant interleukin-2 in therapy for hematologic malignancies.
Dutcher
J P
JP
Albert Einstein Cancer Center, Albert Einstein College of Medicine, Bronx, NY 10467.
Wiernik
P H
PH
D002986:Clinical Trials as Topic; D004167:Diphtheria Toxin / Q000627:therapeutic use*; D006402:Hematologic Diseases / Q000276:immunology / Q000628:therapy*; D006801:Humans; D007376:Interleukin-2 / Q000627:therapeutic use*; D007938:Leukemia / Q000276:immunology / Q000628:therapy*; D008223:Lymphoma / Q000276:immunology / Q000628:therapy*; D015375:Receptors, Interleukin-2 / Q000502:physiology; D011993:Recombinant Fusion Proteins; D011994:Recombinant Proteins / Q000627:therapeutic use
C054780:DAB(486)-interleukin 2; D004167:Diphtheria Toxin; D007376:Interleukin-2; D015375:Receptors, Interleukin-2; D011993:Recombinant Fusion Proteins; D011994:Recombinant Proteins